pharmaceutical cocrystals
DESCRIPTION
Pharmaceutical Cocrystals. 杜新莹 黄箫喃 王倩倩 2012/9/26. Preparation. Review. Characterization. Contents. Pharmaceutical Cocrystals. Reviews. Definition. Molecule. Reviews. Definition. Bonding form. Bonding form. Reviews. Definition. Molecular recognition. T hermodynamics. - PowerPoint PPT PresentationTRANSCRIPT
Pharmaceutical Cocrystals
杜新莹 黄箫喃 王倩倩 2012/9/26
Contents
Pharmaceutical Cocrystals
Review
Preparation Characterization
Definition Reviews
Bonding form
Definition Reviews
Bonding form
Molecule
Definition Reviews
Supermolecular synthon
Intermolecularinteraction
Balance
Thermodynamics
Kinetics Molecular recognition
Hydrogen bondHalogen bond
π stackingVander Waals forces
Formation Mechanism Reviews
Formation Mechanism Reviews
the most important
O-H…X(X= O, N) C-H…X(X= O, N, π) N-H…N
carboxylic acid - carboxylic acid carboxylic acid - pyridine carboxylic acid - amide alcohol – pyridinealcohol - amine
Hydrogen bond
Formation Mechanism Reviews
Heteroatom with lone pair electron(N, O, S)
Halogen bond
Lewis acid halogen atom ( Cl,Br,I )
Lewis acid halogen atom ( Cl,Br,I ) non-covalent
bond
Formation Mechanism Reviews
π stacking
Parallel superposition Parallel displacement
Formation Mechanism Reviews
Vander Waals forces
WeakDirectivitysaturability No
Advantages
Melting point
Solubility
Dissolution rate
Stability Bioavailability
Pharmaceuticalcocrystals
Advantages Melting pointMelting point
51%39%6%4%
Drug processing
MP Change
Cocrystallization
thermal decompositioncrystal form transformation
thermodynamics behavior
Intermolecular forceCrystalline form
accumulation
Advantages
•hydrolysis •oxidation •chemical reaction
•decomposition in high temperature•drying•tabletting
StabilityStability
Equilibrium solubilitykinetic solubilityForm changesBasic media
StabilityStability
Advantages SolubilityDissolution rate
SolubilityDissolution rate
Solid form
Disintegrationdissolve Solution
for low solubility
even saturation
no effect
absorption rate
dissolution rate
dissolution ratetoo low
intenseHigh dissolution velocity danger
Advantages BioavailabilityBioavailability
Solubility
Disslutionrate
Bioavailability
circulatory system
SolubilityAMG517 + sorbic acid
Better solubilitypharmacokineticsCmax: 30 mg/kg
500 mg/kg AUC: 1/2
Bioavailability
carbamazepine + saccharin
Good chemical stability;
Better physical stability than
solvate & anhydrous,
polymorphism
Advantages
Stability2-[4-(4-chloro-2-fluorphenoxy)-phenyl]pyrimidine-4-carboxamide
+glutaric acid
dissolution rate: 18Bioavailability: 3
ExamplesExamples
Design Reviews
Design Reviews
Structural Analysis
molecular conformationCBD:Pharmaceutics molecular arrangement functional group
Molecular associationSupramolecular structure formationMolecular interaction strength
Design Reviews
Ligand Screening
Design Reviews
Structure Prediction
molecular interaction
Cocrystalstructure
Design Reviews
Bonding Effects
Competition sites
Molecular Conformation
Steric effects
Competitive dipole effect
Methods
reactive crystallization
reactive crystallization
neat grinding
solvent-drop grindingcooling
crystallization cooling
crystallization
evaporative crystallizationevaporative
crystallization
slurry crystallization
slurry crystallization
spray crystallization
spray crystallization
DSC
Kofler
Preparation
GrindingGrinding
Preparation
wide applicationhigher yieldhigher crystallinitypolymorphismgreen process
neat grindingsolvent-drop grinding
SublimationSublimation
Preparation
Thermodynamic advantage
Similar solubility
Polymorphism
evaporative crystallizationevaporative
crystallization
cooling crystallization
cooling crystallization
slurry crystallization
slurry crystallization
Stability
Separate precipitation
Ligand screening
Simple opration
Preparation
Growth from the meltGrowth from the melt
Kofler
DSCsimpleefficient
XRD
microscope SS-NMR
thermal analysis
Pharmaceutical cocrystals
characterization
Spectrum
Characterization
Characterization XRD
powder diffraction
single crystal diffraction
• Decide whether there is something New New
Characterization
Hot stage microscopy
polarization microscope
Scanning electron microscope(SEM)• Detect the crystal form of the cocrystrals
Microscope
Characterization
differential thermal analysis (DTA)
thermogravimetric analysis(TGA)
differential scanning calorimetry(DSC)
Thermal Analysis
•Determine thermodynamic parameter&kinetics parameter
Characterization Spectrum
infrared spectrum
raman spectroscopy
•Detect the Structure of cocrystals
•Functional group
ExperimentsExperimentsAPI 的选取非那雄胺( finasteride )水中难溶,属于 BCS Ⅱ类药物 (低溶解度、高渗透度)
已有方法: 包合物、固体分散体( PEG6000 、 Kollidon K25 与非
那雄胺固体分散体和非那雄胺与 β- 环糊精包合物)
目标:提高该药物的溶解度,进而提高该药物的溶出速率及其生物利用度
CCF 的选取
苯甲酸 水杨酰胺 烟酰胺
nicotinamide (NCT)
Preparation and Chracterization
API 与 CCF 的配比
2
Cocrystal?
干磨
1mmol API+1mmol SLC 室温下研磨 30min XRD
结果分析: 8 、 23 附近特征峰得到明显增强,可能有新的物质形成
溶剂挥发法0.5mmol API + 0.5mmol SLC 2mL 乙醇溶解挥发1天 XRD DSC FT-IR
0.5mmol API + 1mmol SLC 2mL 乙醇溶解挥发1天 XRD DSC FT-IR
现象:溶液变粘稠XRD 图分析:两者几乎在相同位置处有新的特征峰出现
,可能产生新的物质DSC 图分析:1:1时发现有 API 的熔点峰出现,1 :
2时则没有FT-IR 图谱结果表明: API 与 SLC 的完全反应配比应为1 : 2,但
是1 : 1时也会产生新的晶体
0.5mmol API + 1mmol NCT 2mL 乙醇溶解挥发2天
XRD DSC FT-IR
XRD 图谱分析:某些位置处的峰强度增强DSC 图谱分析:新的熔点峰(大约12 4℃ )出
现FT-IR 图谱
结果表明: API 与 NCT 可以以1 : 2的比例形成新的物质
溶剂滴加辅助法( solvent-drop grinding )0.5mmol API + 1mmol SLC 100μL 乙醇 边滴加边研磨 XRD 图 DSC 图谱
现象:固体粉末黏在一起
结果分析:1 : 2时 API 与 SLC 确实可以形成新的晶体,但是由于研磨时间、力度等的影响,与溶剂挥发法所制得的晶体仍有一定差距,可以改进。但是,此时 API 与 SLC 所形成的晶体会涉及到晶型的转变。
溶析结晶法( solvent-out crystallization ) 0.25mmol API+0.5mmol BEN 0.8mL 乙醇 待溶解后,加入 4mL 水静置冷却
其余可行方法:熔融结晶法
其余表征方法: TGA 、 1HNMR